High-grade B-cell lymphoma double-hit/triple-hit
MONDO:0850426A B-cell lymphoma that is characterized by the abnormal rearrangement of two genes, MYC gene and either BCL2 or BCL6 genes.
1922 clinical trials for this condition and its sub-types, 14 tagged with High-grade B-cell lymphoma double-hit/triple-hit itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New combo aims to tame side effects in Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a new drug combination (glofitamab plus gemcitabine and oxaliplatin) in about 100 people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see if a better steroid plan can reduce a serious side effect called …
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug cocktail aims to tackle tough blood cancers
Disease control Recruiting nowThis phase II trial is testing a combination of six chemotherapy drugs (clofarabine, etoposide, cyclophosphamide, liposomal vincristine, dexamethasone, and bortezomib) in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, or related cancers that have come back or…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New gene therapy combo tackles aggressive lymphoma in early trial
Disease control Recruiting nowThis early-stage study is testing a new gene therapy called UB-VV400, alone and with the drug rapamycin, in 70 adults with relapsed or refractory large B-cell lymphoma. The main goals are to find safe doses and check for side effects. Researchers will also look for signs that the…
Phase 1 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:45 UTC